Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antibody-Drug Conjugate
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its ADC Payload Technology
Details : Lonza will integrate Simris’ antibody-drug conjugate payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Antibody-Drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?